Estrogen receptor-negative and human epidermal growth factor receptor 2-negative breast cancer tissue have the highest Ki-67 labeling index and EGFR expression: Gene amplification does not contribute to EGFR expression

2005 ◽  
Author(s):  
Shinobu Umemura ◽  
Susumu Takekoshi ◽  
Yasuhiro Suzuki ◽  
Yuki Saitoh ◽  
Yutaka Tokuda ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Estrogen Receptor ◽  
Epidermal Growth Factor Receptor ◽  
Growth Factor Receptor ◽  
Breast Cancer Tissue ◽  
Cancer Tissue ◽  
Ki 67 ◽  
Egfr Expression ◽  
Epidermal Growth ◽  
Estrogen Receptor Negative

scholarly journals Combined High Resistin and EGFR Expression Predicts a Poor Prognosis in Breast Cancer

2020 ◽  
Vol 2020 ◽  
pp. 1-11
Author(s):  
Yue Zeng ◽  
Chih-Hsin Tang ◽  
Yan Wang ◽  
Hua-Jun Lu ◽  
Bi-Fei Huang ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Epidermal Growth Factor Receptor ◽  
Growth Factor ◽  
Growth Factor Receptor ◽  
Molecular Classification ◽  
Breast Cancer Tissue ◽  
Her2 Status ◽  
Cancer Tissue ◽  
Egfr Expression ◽  
Epidermal Growth

Elevated levels of resistin and epidermal growth factor receptor (EGFR) facilitate the development of breast cancer, although there are no reports of any correlation between these proteins. This study analyzed 392 human breast cancer tissue specimens and 42 samples of adjacent normal tissue. Rates of positive and strongly positive resistin expression were significantly higher in breast cancer tissue than in the adjacent nontumor tissue (83.2% vs. 23.8% and 20.9% vs. 0.0%, respectively; P < 0.001 for both comparisons). Positive resistin expression was significantly associated with tumor size, grade, stage, estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor 2 (HER2) status, and molecular classification; strongly positive resistin expression was associated with tumor grade, ER, PR, HER2 status, and molecular classification. Significantly positive correlations were observed between positive and strongly positive resistin expression and corresponding levels of EGFR expression. Relapse-free and overall survival was worse for patients with high levels of both proteins than for those with high levels of only one protein or normal levels of both proteins. Our evidence suggests that combined high levels of resistin and EGFR expression correlate with survival in patients with breast cancer.

Expression of androgen receptor and epidermal growth factor receptor in invasive breast cancer: A retrospective study of 1,438 patients from China.

2017 ◽  
Vol 35 (15_suppl) ◽  
pp. e12587-e12587
Author(s):  
Junqing Chen ◽  
Zhanhong Chen ◽  
Xiaojia Wang
Keyword(s):  
Breast Cancer ◽  
Epidermal Growth Factor Receptor ◽  
Retrospective Study ◽  
Androgen Receptor ◽  
Invasive Breast Cancer ◽  
Growth Factor Receptor ◽  
Ki 67 ◽  
Egfr Expression ◽  
Significant Difference ◽  
Epidermal Growth

e12587 Background: Triple-negative breast cancer (TNBC) is lack of clinically efficient targeted therapies and usually more aggressive with higher rate of distant metastasis and poor overall survival as compared with other breast cancer subtypes. Recent evidence demonstrates that androgen receptor (AR) and epidermal growth factor receptor (EGFR) are involved in the pathogenesis of TNBC. The aim of this study was to explore the expression of AR and EGFR in invasive breast cancer and evaluate the potential of AR and EGFR as biomarkers in TNBC. Methods: In this retrospective study, we analyzed 1438 patients with invasive breast cancer in our hospital from 2015 to 2016. Estrogen receptor (ER) expression, progesterone receptor (PR) expression, Ki-67 index, AR and EGFR expression were detected by immunohistochemical assay. HER2 state was determined by immunohistochemical and FISH assay. χ2 test was used for the analysis. Results: Among 1438 breast cancer patients, 272 (18.9%) cases were TNBC and 1165 (81.0%) cases were non-TNBC. TNBC patients had a low AR expression as compared with non-TNBC patients (29.8% vs 90.2%). There was a significant difference in AR expression in TNBC compared in non-TNBC ( P= 0.000). In contrast, TNBC patients had a high EGFR expression as compared with non-TNBC patients (90.9% vs 21.1%) ( P= 0.000). There was also a significant difference in Ki-67 index in TNBC compared in non-TNBC (89.9% vs 70.1%) ( P= 0.000). AR-positive TNBC patients had a low Ki-67 index expression as compared to AR-negative TNBC (82.7% vs 93.6%). No significant difference of EGFR expression was found between AR-positive TNBC and AR-negative TNBC. Conclusions: AR expression is associated with Ki-67 index and may be as a potential biomarker for targeted therapy in AR-positive TNBC patients.

Sign in / Sign up

Export Citation Format

Share Document